Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
Apply on Grants.gov →Application closes January 11, 2027
- Posted
- August 31, 2026
- Closes
- January 11, 2027
- Award ceiling
- $700,000
- Program funding
- $4,400,000
- Expected awards
- 4
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.394, 93.395
- Category
- Health
- Archives
- March 11, 2027
Program funding history
Awards made under Assistance Listing 93.394 (one of 2 on this opportunity) across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $595.6M
- FY2026 obligated
- $548.5M
- FY2027 (to date) obligated
- $0
- Awards in window
- 1,877
Top recipients: Regents of the University of California, San Francisco, the, Fred Hutchinson Cancer Center, The Johns Hopkins University, The Leland Stanford Junior University, The Univeristy of Texas M.d. Anderson Cancer Center
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms.
To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.
Who can apply
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized tribal governments)
- Small businesses
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Independent school districts
- Special district governments
- Public housing authorities/Indian housing authorities
- Private institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- City or township governments
- Public and State controlled institutions of higher education
- State governments
- County governments
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations: Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.
New to federal funding? How to read an announcement · Who can apply · How grants work
Remind me before this closes
One email about a week before this grant closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
- HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing